ReviewInternational journal of chronic obstructive pulmonary disease2007
Role of tiotropium in the treatment of COPD.
Review in International journal of chronic obstructive pulmonary disease, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.Respiratory research · 2011Trial
- Article
- Tiotropium in chronic obstructive pulmonary disease - a review of clinical development.Respiratory research · 2020Review
- Tiotropium inhibits proinflammatory microparticle generation by human bronchial and endothelial cells.Scientific reports · 2019Article
- Pharmacological Modulation of Endotoxin-Induced Release of IL-26 in Human Primary Lung Fibroblasts.Frontiers in pharmacology · 2019Article
- The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease.Tuberculosis and respiratory diseases · 2017Review
- Extrinsic Threshold PEEP Reduces Post-exercise Dyspnea in COPD Patients: A Placebo-controlled, Double-blind Cross-over Study.Cardiopulmonary physical therapy journal · 2011Article
- Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting.International journal of chronic obstructive pulmonary disease · 2009Article
- Which bronchodilator in COPD?International journal of chronic obstructive pulmonary disease · 2007Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tiotropium is a potent, long-acting, selective anticholinergic bronchodilator. Treatment with tiotropium produces sustained improvements in lung function, particularly FEV1 (peak, trough, average, and area under the curve) compared with either placebo or ipratropium in patients with moderate to severe COPD. Preliminary evidence suggests that treatment with tiotropium may slow the rate of decline in FEV1, but this finding awaits confirmation. Tiotropium reduces lung hyperinflation, with associated improvements in exercise capacity. Tiotropium, compared with either placebo or ipratropium, improves a variety of patient-centered outcomes, including subjective dyspnea ratings and HRQL scores. Tiotropium reduces the frequency of COPD exacerbations and of hospitalizations due to exacerbations, but has not been shown to reduce all-cause mortality. Compared with the long-acting bronchodilators, tiotropium provides incrementally better bronchodilation, but it is not clearly superior in terms of patient-centered outcomes. Tiotropium has a good safety profile; however patients with severe cardiac disease, bladder outlet obstruction, or narrow angle glaucoma were excluded from all studies. Medico economic analyses suggest that treatment with tiotropium may also be cost-effective, primarily by reducing costs associated with hospitalizations.
Indexed as
Identifiers
18044681PMC2695619W1760817196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.